Latest news

  • Aug 04, 2022 Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates View
  • Jul 27, 2022 Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 View
  • Jul 22, 2022 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) View
View All News

Clinical platforms

Our T-cell-based immunotherapy technology platforms are potentially applicable to many solid tumor types and blood cancers. Each platform is focused on leveraging patient-specific cells to recognize and attack diverse cancer cells that are unique to each patient. Unlike targeted cell therapies that act on shared antigen targets common to certain tumors, our polyclonal T cells are personalized therapies designed to target a variety of neoantigens (new proteins generated by tumor mutations) that are unique to the patient or tumor.

TIL therapy is our lead T-cell-based immunotherapy platform. We are currently investigating TIL therapy in clinical trials in multiple advanced solid tumor cancers. We are also advancing genetically modified TIL therapies as a next-generation approach for solid tumor cancers.

Our peripheral blood lymphocyte (PBL) therapy platform for blood cancers is based on polyclonal T cells that are collected, amplified and reinvigorated from a patient’s blood sample.


Iovance Cell Therapy Center (iCTC)

Our investigational TIL therapy is manufactured at our state-of-the-art, 136,000–square-foot Cell Therapy Center, located in Philadelphia, PA, using proprietary good manufacturing practices (GMP).

TIL and PBL therapies are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.